Back
Top 3%
18.1%
Top 0.2%
15.0%
Top 65%
8.0%
#1
8.0%
Top 24%
6.6%
Top 4%
6.1%
#1
6.1%
Top 4%
4.3%
Top 9%
4.3%
Top 15%
2.0%
Top 5%
2.0%
Top 0.2%
1.6%
Top 34%
1.4%
Top 4%
1.4%
Top 8%
1.0%
Top 13%
1.0%
Top 53%
1.0%
Top 95%
0.7%
Top 8%
0.7%
Top 16%
0.7%
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
2022-11-10
health economics
Title + abstract only
View on medRxiv
Show abstract
IntroductionCurrent options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. MethodsWe used a Markov model to estimate the incremental cost-effectiveness of three regimens containing bedaquiline, pretomanid and linezolid (BPaL) with and without moxifloxacin (BPaLM) or clofazim...
Predicted journal destinations
1
PLOS Global Public Health
287 training papers
2
BMJ Global Health
95 training papers
3
PLOS ONE
1737 training papers
4
PLOS Medicine
95 training papers
5
BMJ Open
553 training papers
6
PLOS Neglected Tropical Diseases
166 training papers
7
eClinicalMedicine
55 training papers
8
BMC Medicine
155 training papers
9
Clinical Infectious Diseases
219 training papers
10
BMC Public Health
148 training papers
11
Proceedings of the National Academy of Sciences
100 training papers
12
The Lancet Global Health
24 training papers
13
eLife
262 training papers
14
BMC Health Services Research
43 training papers
15
Vaccine
140 training papers
16
Open Forum Infectious Diseases
124 training papers
17
Nature Communications
483 training papers
18
Scientific Reports
701 training papers
19
The Lancet Infectious Diseases
57 training papers
20
The Journal of Infectious Diseases
137 training papers